Congress caps drug costs for patients, expands Medicare negotiation power

What it does

This bill expands Medicare's drug price negotiation program to cover more drugs (up to 50 per year instead of a lower number), applies it to commercial insurance plans on a voluntary basis, extends inflation rebates to drugs sold outside Medicare, and caps out-of-pocket costs for prescription drugs in private insurance at $2,000 per year starting in 2027, with insulin capped at $35 per 30-day supply. Ordinary people with private insurance and Medicare beneficiaries benefit through lower drug costs and predictable out-of-pocket limits; pharmaceutical manufacturers face lower negotiated prices.

Why we flagged it

The bill's operative mechanism is a three-part price restraint: expanding Medicare negotiation authority, extending inflation rebates to commercial markets, and capping patient out-of-pocket costs. These are direct price controls and consumer protections, not subsidies or deregulation.

What the text implies

• Voluntary participation by commercial insurers may create a two-tier system: plans that opt in (lower drug costs) vs. plans that opt out (higher costs). Public disclosure of opt-outs may pressure insurers to participate, but the mechanism is permissive, not mandatory.
• The bill repeals Section 71203 of Public Law 119–21, reversing a prior restriction on the negotiation program. This is a direct legislative reversal of a recent change, signaling ongoing political volatility in drug pricing policy.

The full analysis lists 5 implications of this text.

Who stands to gain

Medicare beneficiaries (lower drug costs); Uninsured and underinsured individuals (if commercial plans pass savings through); Patients with chronic conditions requiring expensive drugs (insulin, biologics)